ID: ALA3088089

Max Phase: Preclinical

Molecular Formula: C36H45NO3

Molecular Weight: 539.76

Molecule Type: Small molecule

Representations

Canonical SMILES:  C[C@]12CC[C@@]3(C[C@@H]1CC[C@@H]1[C@@H]2CC[C@]2(C)C(=O)CC[C@@H]12)CN(Cc1ccccc1)[C@@H](Cc1ccccc1)C(=O)O3

Standard InChI:  InChI=1S/C36H45NO3/c1-34-19-20-36(22-27(34)13-14-28-29-15-16-32(38)35(29,2)18-17-30(28)34)24-37(23-26-11-7-4-8-12-26)31(33(39)40-36)21-25-9-5-3-6-10-25/h3-12,27-31H,13-24H2,1-2H3/t27-,28-,29-,30-,31-,34-,35-,36+/m0/s1

Standard InChI Key:  HDSBPWALSVPVOL-CYQIHANRSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 539.76

Molecular Weight (Monoisotopic): 539.3399

AlogP: 7.01

#Rotatable Bonds: 4

Polar Surface Area: 46.61

Molecular Species: NEUTRAL

HBA: 4

HBD: 0

#RO5 Violations: 2

HBA (Lipinski): 4

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 6.81

CX LogP: 7.80

CX LogD: 7.70

Aromatic Rings: 2

Heavy Atoms: 40

QED Weighted: 0.39

Np Likeness Score: 1.26

References

1. Djigoué GB, Kenmogne LC, Roy J, Poirier D..  (2013)  Synthesis of 3-spiromorpholinone androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.,  23  (23): [PMID:24144853] [10.1016/j.bmcl.2013.09.072]

2. Djigoué GB, Kenmogne LC, Roy J, Maltais R, Poirier D..  (2015)  Design, chemical synthesis and biological evaluation of 3-spiromorpholinone/3-spirocarbamate androsterone derivatives as inhibitors of 17β-hydroxysteroid dehydrogenase type 3.,  23  (17): [PMID:26277760] [10.1016/j.bmc.2015.07.049]

Source

Source(1):

• Scientific Literature